Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1250 participants.

Also called NCT06260722

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06260722
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Canada, Mexico, Puerto Rico (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06260722. Randomized; no masking; primary purpose treatment. Start 2024-02-21 (actual); primary completion 2026-08-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Retatrutide
Intervention (Drug)
Semaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06260722
Content hash
13def72c6f555fd803b5ca08b71db4df35f45868a62d2f10f75fdd7eb2fdeb39